BRIEF published on 04/24/2026 at 07:05, 1 month 24 days ago BB Biotech AG Reports Q1 2026 Interim Results Drug Development Net Loss Investment Portfolio BB Biotech Q1 2026
BRIEF published on 04/24/2026 at 07:05, 1 month 24 days ago BB Biotech Q1 2026 Achievements and Strategic Shifts Net Asset Value Portfolio Repositioning New Investments BB Biotech Performance Dividend Inclusion
PRESS RELEASE published on 04/24/2026 at 07:00, 1 month 24 days ago EQS-Adhoc: BB Biotech AG publishes its interim report BB Biotech AG publishes its interim report for the first quarter of 2026, showing a net loss of CHF 21 mn compared to CHF 241 mn in the same period of 2025 Investment Company BB Biotech AG Interim Report Results Loss
PRESS RELEASE published on 04/24/2026 at 07:00, 1 month 24 days ago BB Biotech Q1 2026: Share price outperformance, narrowing discount and active portfolio repositioning BB Biotech AG reports Q1 2026 results with share price outperformance, narrowing discount, and active portfolio repositioning. Eleven new investments made in biotech sector Share Price BB Biotech AG Investments Portfolio Repositioning Q1 2026
BRIEF published on 03/19/2026 at 17:45, 2 months 30 days ago BB Biotech AG's AGM Approves Proposals and Dividend Annual General Meeting Investment Strategy Board Re-election Dividend Approval BB Biotech
PRESS RELEASE published on 03/19/2026 at 17:40, 2 months 30 days ago Shareholders at BB Biotech AG’s AGM vote in favor of all proposals and approve the dividend of CHF 2.25 per share Shareholders at BB Biotech AG's AGM approve CHF 2.25 dividend per share. Board proposals endorsed. Re-election of board members Shareholders Dividend AGM BB Biotech AG Board Proposals
BRIEF published on 02/20/2026 at 07:05, 3 months 26 days ago BB Biotech AG Releases 2025 Annual Report Dividend Proposal Biotechnology Sector Net Profit Increase BB Biotech 2025 Annual Report
BRIEF published on 02/20/2026 at 07:05, 3 months 26 days ago BB Biotech's 2025 Annual Report Highlights Strong Financial Gains Annual Report Portfolio Value Shareholder Returns BB Biotech Financial Gains
PRESS RELEASE published on 02/20/2026 at 07:00, 3 months 26 days ago EQS-Adhoc: BB Biotech AG publishes its 2025 annual report BB Biotech AG releases its 2025 annual report, reporting a strong performance with a +34.2% total return in CHF. The annual report includes detailed information on the biotechnology sector and the company's investments Financial Results Investment BB Biotech AG Biotechnology Sector 2025 Annual Report
PRESS RELEASE published on 02/20/2026 at 07:00, 3 months 26 days ago Annual Report 2025: BB Biotech delivers strong performance and portfolio value realization BB Biotech AG's Annual Report 2025 showcases strong performance and portfolio value realization. Shareholder returns, active capital management, and refined investment processes highlighted BB Biotech AG Portfolio Value Shareholder Returns Annual Report 2025 Investment Processes
Published on 06/18/2026 at 18:00, 3 hours 54 minutes ago BEACN Closes Second Series Under Loan Program and Previews BEACN App Version 1.4
Published on 06/18/2026 at 17:30, 4 hours 24 minutes ago Sekur Private Data Appoints Nathan R. Price as Special Advisor for Diplomacy & Intelligence
Published on 06/18/2026 at 15:50, 6 hours 4 minutes ago Pentagon I Capital Corp. and Prospectiva Resources Ltd. Announce Financing
Published on 06/18/2026 at 15:00, 6 hours 54 minutes ago Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, Announces Positive Results of Preclinical Study of Coca for Weight Gain Prevention
Published on 06/18/2026 at 14:30, 7 hours 24 minutes ago Voting Results from Solitario Resources Corp Annual Meeting Held June 17, 2026
Published on 06/18/2026 at 18:30, 3 hours 23 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 06/18/2026 at 18:25, 3 hours 28 minutes ago Sopra Steria achives Level 2 Responsible Digital Label and strengthens its responsible digital strategy
Published on 06/18/2026 at 17:45, 4 hours 9 minutes ago 2CRSi SA: 2CRSi disputes the content of the document published by Grizzly Research and is preparing a substantiated response calling for the suspension of trading in its shares
Published on 06/18/2026 at 18:00, 3 hours 54 minutes ago Outstanding shares and voting rights statement at 31 May 2026
Published on 06/18/2026 at 17:45, 4 hours 9 minutes ago EURAZEO INVESTS IN LAURALU, A PAN-EUROPEAN PROVIDER OF DEPLOYABLE INDUSTRIAL INFRASTRUCTURE
Published on 06/18/2026 at 17:38, 4 hours 15 minutes ago Statement of transactions in own shares from June 8, 2026 to June 12, 2026
Published on 06/18/2026 at 09:06, 12 hours 48 minutes ago Eiffage, member of the NSORe joint venture, wins the contract for a converter station for the NSC2 offshore grid connection project in Germany
